The global nanomedicine market size was estimated at USD 138.8 billion in 2016. Technological advancements coupled with relevant applications in early disease diagnosis, preventive intervention, and prophylaxis of chronic as well as acute disorders are expected to bolster growth in this market. Nanotechnology involves the miniaturization of larger structures and chemicals at a nanometric scale which has significantly revolutionized drug administration, thus influencing adoption of the technology through to 2025.
Expected developments in nanorobotics owing to the rise in funding from the government organizations are expected to induce potential to the market. Nanorobotics engineering projects that are attempting to target the cancer cells without affecting the surrounding tissues are anticipated to drive progress through to 2025.
U.S. nanomedicine market by product, 2013 - 2025 (USD Billion)
Ability of the nanotechnology to serve in diagnostics as well as the therapeutic sector at the same time as a consequence of its characteristic principle is anticipated to augment research in this sector. Furthermore, utilization of DNA origami for healthcare applications is attributive to the projected growth.
Potential pipeline of products based on the nanomolecules and associated technologies is anticipated to drive market with potential avenues of growth. The presence of around 40% of products in phase II of clinical development, is anticipated to result in a number of key commercialization over the coming decade influencing revenue generation over the forecast period. The customized treatment options available for eradication of genetic abnormalities also makes this technology a substantial option for precision medicine.
Therapeutics accounted for the major share in revenue in 2016 owing to the presence of several products falling in this category. Drugs and devices as well as the drug delivery systems fall under the therapeutic category for the treatment of several diseases.
Due to the unique physicochemical properties exhibited by nanoparticles, these serve as a promising technology for delivery of drugs to desired site of action. Additionally, nanotechnology-enabled drug delivery system enables drug administration with excellent advantages due to characteristic features of enhancement of the cellular penetration of given drug and lowering its toxicity.
These benefits are anticipated to shed positive light on nanotechnology for drug delivery as an emerging product line, thereby impacting growth during the forecast period. Development of novel delivery products by utilizing the different kinds of nanoparticles is expected to fuel growth in this segment
Application wise the segmentation encompasses oncology, infectious diseases, cardiology, orthopedics, and other applications. Oncology dominated with respect to revenue share of about 47% in 2016.
Abundance of products present in the clinical phases of development, for cancer treatment coupled with advancements for introduction of theranostic particles and devices are attributive for the larger share of cancer diseases. The technique possesses the ability to serve as a tool for active and passive targeting of cancer.
However, cardiology is anticipated to exhibit the fastest progress with a CAGR of approximately 11.7% over the forecast period owing to the presence of opportunities such as demand for specific therapeutic nanovectors, nanostructured stents, and implants for tissue regeneration.
There are different types of nanomolecules that can be used in the healthcare sector. These molecules include quantum dots, nanoparticles, nanoshells, nanotubes, and nanodevices. Nanoparticles comprise metal & metal oxide nanoparticles, liposomes, dendrimers, conjugated polymers.
Application of the nanoparticles in different areas of healthcare is expected to boost growth in the coming years. Ability of these molecules to get attached to the chemical moieties in the form of scaffolds enables them to perform diverse functions. Utilization of nanoparticles for active targeting by binding it to ligands of a cell receptor is also one of the important tools of nanotechnology.
Metal & metal oxide nanoparticles are likely to witness high demand in this market owing to their widespread usage in diagnostics. Research carried out in order to develop theranostics is anticipated to influence industrial growth.
North America dominated the nanomedicine market with a revenue share of over 42% owing to the presence of increasingly growing partnerships between enterprises operating herein and nanomedicine startup organizations. Furthermore, support from the government entities coupled with higher R&D spending is attributive for the largest share of region in the industrial space.
Nanomedicine market, by region, 2016 (%)
However, Asia Pacific is expected to witness lucrative growth through to 2025 as a result of rise in number of research grants and increase in demand for prophylaxis of life-threatening diseases. Moreover, rise in the number of venture capital investors from developing economies of this region and increasing international research collaborations are anticipated to propel growth in nanotechnology-based healthcare industry.
Major players operating in this market are Combimatrix Corp, Ablynx NV, Abraxis Bioscience Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd, Arrowhead Research, GE Healthcare, Merck & Co. Inc., Pfizer Inc., and Nanosphere, Inc. These players are involved in gaining the U.S. FDA approvals in order to enhance the market presence.
For instance, in February 2017, the company received approval from the European Commission for its REVLIMID (lenalidomide) as monotherapy for treatment of patients with adult patients with multiple myeloma. This approval allows company to distribute its product in European countries, thereby enhancing company’s presence in the Europe market.
Base year for estimation
Actual estimates/Historic data
2013 - 2016
2017 - 2025
Revenue in USD Billion & CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, UK, Germany, Japan, China, Brazil, South Africa.
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you are looking for specific or additional market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at regional & country level and provides an analysis on the latest trends and opportunities in each of the sub-segments from 2013 to 2025. For the purpose of this report, Grand View Research has segmented the nanomedicine market on the basis of product, application, nanomolecule type, and regions:
Product Outlook (Revenue, USD Billion; 2013 - 2025)
Application Outlook (Revenue, USD Billion; 2013 - 2025)
Nanomolecule Type Outlook (Revenue, USD Billion; 2013 - 2025)
Metal & Metal Oxide Nanoparticles
Iron Oxide Nanoparticles
Gadolinium Oxide Nanoparticles
Targeted Drug Delivery
Cell & Phantom Imaging
Polymers & polymer drug conjugates
Regional Outlook (Revenue, USD Billion; 2013 - 2025)
Middle East and Africa (MEA)
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.